N/A
N=60
Acute Exercise and the Cerebral Metabolic Response in Aging and Alzheimer's Disease
Healthy Aging · Alzheimer Disease
Bottom Line
View on ClinicalTrials.gov: NCT04299308 ↗Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Jul 2025
Primary outcome: Primary: Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) Metabolism (Standard Uptake Value Ratio) — -0.0514; -0.0667 SUVR
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Aerobic Exercise (Behavioral)
- Age
- Adult, Older Adult · 60+ yrs
- Sex
- All
- Sponsor
- University of Kansas Medical Center
- Primary completion
- Oct 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) Metabolism (Standard Uptake Value Ratio) |
-0.0514; -0.0667 | — |
| SECONDARY Lactate Area Under the Curve |
40.3; 97.0 | — |
| SECONDARY Brain-derived Neurotrophic Factor (BDNF) Change |
610.2; 353.3 | — |
Summary
The overall goal is to characterize the acute exercise response as it relates to brain glucose metabolism in aging and Alzheimer's Disease (AD). The study team will also examine lactate metabolism, relationships with cognition, and the effect of exercise intensity.
Eligibility Criteria
Inclusion Criteria
- Age 60 and older
- Stable medication doses (>1month)
- Post-menopausal
- Diagnosis of either Nondemented (CDR 0) or Probable AD (CDR 0.5 or 1 only)
Exclusion Criteria
- Inability to provide consent
- Diagnosis of insulin-dependent (Type 1) Diabetes Mellitus
- Recent ischemic heart disease (<2 years)
- Diagnosis of an clinically significant chronic disease including cardiovascular disease (CVD), other metabolic diseases (e.g., thyroid), cancer, human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome
- Excluded from or unable to complete an MRI scan
- Any Neurological disorders that have the potential to impair cognition or brain metabolism (e.g., Parkinson's disease, stroke defined as a clinical episode with neuroimaging evidence in an appropriate area to explain the symptoms).
- Clinically significant depressive symptoms that may impair cognition, abnormalities in B12, rapid plasma regain (RPR), or thyroid function that may impair cognition, use of psychoactive and investigational medications, and significant visual or auditory impairment
Data sourced from ClinicalTrials.gov (NCT04299308). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.